
The ASR device was approved by the U.S. Food & Drug Administration (FDA) via the 510(K) process, which allows a manufacturer to obtain market approval with very little clinical testing of a device – including no human testing – if it is “substantially similar” to another product already on the market. The 510(k) approval process has received a great deal of criticism in recent years. In fact, shortly after the DePuy hip implant recall was issued, an internal FDA review found numerous flaws with the process. Just this past February, a study published in the Archives of Internal Medicine found that the majority of high risk medical device recalls over the past five years involved products subject to the streamlined 510(K) approval process.
Data from the National Joint Registry of England and Wales showed that 1 out of every 8 patients (12%-13%) who had received the devices had to undergo revision surgery within five years of receiving. The DePuy ASR Hip Resurfacing System was used in the U.K., but was not approved by for sale in the U.S. A number of individuals who have experienced problems with their DePuy metal hip are now reviewing the potential for DePuy ASR hip replacement lawsuits against the manufacturer, alleging that the hip implant was defectively designed and was sold with inadequate warnings about the risk of complications.
No comments:
Post a Comment